Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

被引：0

作者：

Flinn, Ian ^{[1
]}

Brunvand, Mark ^{[2
]}

Dyer, Martin J. S. ^{[3
]}

Hillman, Peter ^{[4
]}

Jones, Jeffrey ^{[5
]}

Lymp, James ^{[6
]}

Elhamy, Mostafa ^{[6
]}

Vosganian, Gregory ^{[6
]}

Huang, Jane ^{[6
]}

Kipps, Thomas J. ^{[7
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Colorado Blood Canc Inst, Denver, CO USA

[3] Univ Leicester, Leicester, Leics, England

[4] St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England

[5] Ohio State Univ, Sch Med, Columbus, OH 43210 USA

[6] Genentech Inc, San Francisco, CA 94080 USA

[7] Univ Calif San Diego, La Jolla, CA 92093 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
Flinn, Ian W.
Gribben, John G.
Dyer, Martin J. S.
Wierda, William
Maris, Michael B.
Furman, Richard R.
Hillmen, Peter
Rogers, Kerry A.
Iyer, Swaminathan Padmanabhan
Quillet-Mary, Anne
Ysebaert, Loic
Walter, Harriet S.
Verdugo, Maria
Klein, Christian
Huang, Huang
Jiang, Yanwen
Lozanski, Gerard
Pignataro, Daniela Soriano
Humphrey, Kathryn
Mobasher, Mehrdad
Kipps, Thomas J.
BLOOD, 2019, 133 (26) : 2765 - 2775
[22] Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Seymour, John Francis
Davids, Matthew Steven
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Miller, Thomas P.
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary Ann
Huang, David C. S.
Darden, David E.
Gressick, Lori A.
Nolan, Cathy E.
Yang, Jianning
Busman, Todd A.
Graham, Alison M.
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[23] Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
Touzeau, Cyrille
Chanan-Khan, Asher Alban Akmal
Roberts, Andrew Warwick
Agarwal, Amit
Facon, Thierry
Lebovic, Daniel
Moreau, Philippe
Darden, David E.
Morris, Lura J.
Ross, Jeremy A.
Salem, Ahmed H.
Munasinghe, Wijith
Zhu, Ming
Leverson, Joel
Enschede, Sari H.
Humerickhouse, Rod
Harrison, Simon J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[24] ABT-199 (GDC-0199) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA: HIGH RESPONSE RATES AMONG PATIENTS WITH HIGH RISK DISEASE FEATURES INCLUDING UNMUTATED IGHV
Seymour, J. F.
Davids, M. S.
Pagel, J. M.
Kahl, B. S.
Wierda, W. G.
Puvvada, S.
Gerecitano, J. F.
Kipps, T. J.
Anderson, M. A.
Huang, D. C.
Rudersdorf, N. K.
Gressick, L. A.
Montalvo, N. P.
Yang, J.
Zhu, M.
Dunbar, M.
Cerri, E.
Enschede, S. H.
Humerickhouse, R. A.
Roberts, A. W.
HAEMATOLOGICA, 2014, 99 : 249 - 249
[25] THE BCL-2 INHIBITOR ABT-199 (GDC-0199) IS ACTIVE AND WELL-TOLERATED IN ULTRA HIGH-RISK RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Roberts, A.
Davids, M.
Pagel, J.
Kahl, B.
Wierda, W.
Miller, T.
Gerecitano, J.
Kipps, T.
Anderson, M.
Huang, D.
Darden, D.
Gressick, L.
Nolan, C.
Yang, J.
Busman, T.
Graham, A.
Cerri, E.
Enschede, S.
Humerickhouse, R.
Seymour, J.
HAEMATOLOGICA, 2013, 98 : 473 - 473
[26] ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control.
Seymour, John Francis
Davids, Matthew Steven
Pagel, John M.
Kahl, Brad S.
Wierda, William G.
Puvvada, Soham
Gerecitano, John F.
Kipps, Thomas J.
Anderson, Mary Ann
Huang, David C. S.
Rudersdorf, Nikita
Gressick, Lori A.
Montalvo, Nicholas P.
Yang, Jianning
Zhu, Ming
Dunbar, Martin
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod
Roberts, Andrew Warwick
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] A phase 2 open-label study of the efficacy of ABT-199 (GDC-0199) in patients with relapsed or refractory (R/R) chronic lymphosytic leukemia (CLL) harboring 17p deletion
Wierda, William G.
Seymour, John Francis
Roberts, Andrew Warwick
Puvvada, Soham
Davids, Matthew Steven
Wong, Shekman
Zhu, Ming
Carrl, Elisa
Humerickhouse, Rod
Stilgenbauer, Stephan
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[28] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
Ryan, Christine E.
Brander, Danielle M.
Barr, Paul M.
Tyekucheva, Svitlana
Hackett, Liam R.
Collins, Mary C.
Fernandes, Stacey M.
Ren, Yue
Zhou, Yinglu
McDonough, Mikaela M.
Walker, Heather A.
McEwan, Monica R.
Abramson, Jeremy S.
Jacobsen, Eric D.
LaCasce, Ann S.
Fisher, David C.
Brown, Jennifer R.
Davids, Matthew S.
LEUKEMIA, 2023, 37 (04) : 835 - 842
[29] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
Christine E. Ryan
Danielle M. Brander
Paul M. Barr
Svitlana Tyekucheva
Liam R. Hackett
Mary C. Collins
Stacey M. Fernandes
Yue Ren
Yinglu Zhou
Mikaela M. McDonough
Heather A. Walker
Monica R. McEwan
Jeremy S. Abramson
Eric D. Jacobsen
Ann S. LaCasce
David C. Fisher
Jennifer R. Brown
Matthew S. Davids
Leukemia, 2023, 37 : 835 - 842
[30] Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Rogers, Kerry A.
Huang, Ying
Ruppert, Amy S.
Awan, Farrukh T.
Heerema, Nyla A.
Hoffman, Corinne
Lozanski, Gerard
Maddocks, Kami J.
Moran, Mollie E.
Reid, Mark A.
Lucas, Margaret
Woyach, Jennifer A.
Whitlow, W. Thomas
Jones, Jeffrey A.
Byrd, John C.
BLOOD, 2018, 132 (15) : 1568 - 1572

← 1 2 3 4 5 →